Scholar Rock Holding (SRRK) Total Non-Current Liabilities (2017 - 2021)
Scholar Rock Holding's quarterly Total Non-Current Liabilities came in at $115.4 million in Q2 2021, down 3.87% quarter-over-quarter from $120.0 million in Q1 2021.
Scholar Rock Holding has reported Total Non-Current Liabilities for 4 years, with the latest figure at $115.4 million in Q2 2021.
- For the quarter ending Q2 2021, Total Non-Current Liabilities changed N/A year-over-year to $115.4 million; the trailing twelve-month figure through Jun 2021 stood at $115.4 million (changed N/A YoY), and the FY2020 full-year result was $127.5 million, up 52.78% from the prior year.
- Total Non-Current Liabilities for Q2 2021 stood at $115.4 million, down from $120.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $127.5 million in Q4 2020, with the low at $5.9 million in Q4 2017.
- Average Total Non-Current Liabilities over 4 years is $90.5 million, with a median of $115.4 million recorded in 2021.
- Peak annual rise in Total Non-Current Liabilities reached 52.78% in 2020, while the deepest fall reached 52.78% in 2020.
- Tracing SRRK's Total Non-Current Liabilities over 4 years: stood at $5.9 million in 2017, then jumped by 1317.16% to $83.5 million in 2019, then surged by 52.78% to $127.5 million in 2020, then retreated by 9.52% to $115.4 million in 2021.
- The last three Total Non-Current Liabilities figures came in at $115.4 million (Q2 2021), $120.0 million (Q1 2021), and $127.5 million (Q4 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 115.39 Mn |
| Mar 31, 2021 | 120.04 Mn |
| Dec 31, 2020 | 127.53 Mn |
| Dec 31, 2019 | 83.47 Mn |
| Dec 31, 2017 | 5.89 Mn |